This study will be investigated what mechanism of action Dienogest has. The growth of the follicles, the endometrium, the hormones in the blood and the mucus that is produced by the cervix that will be looked upon. Four different dosages of Dienogest (0.5 mg, 1 mg, 2 mg and 3 mg) will be investigated in healthy young women over two cycles, or up to a maximum of 72 days.
- Signed informed consent - Body-Mass-Index (BMI): 18 - 30 kg/m² - Healthy female volunteers - Age 18-35 years (smoker not older than 30 years, inclusive) - At least 3 months since delivery, abortion or lactation - Willingness to use non-hormonal methods of contraception during entire study
- Contraindications for use of progesterone-only pills or combined oral contraceptives (e.g. history of venous/arterial thromboembolic disease) - Use of systemic or topical medications or substances which oppose the study objectives or which might influence them within 4 weeks prior to start of the pre-treatment cycle - Clinically relevant findings (blood pressure, physical and gynecological examination, laboratory examination)
Groningen, Netherlands, 9713 GZ
E-mail: [email protected]
Phone: Not Available
A double-blind, randomized, dose-controlled study to evaluate pharmacodynamic properties of four oral doses of dienogest (DNG) in 100 healthy young female volunteers over a period of two cycles up to a maximum of 72 days